InvestorsHub Logo
icon url

BonelessCat

12/23/16 11:04 PM

#166566 RE: Jhawker #166565

Yep. Suggesting to a shareholder during the formative years a potential for a minimum of $15 billion valuation should all benchmarks across two drug platforms be met all the way to market is hardly a bold or irresponsible call from a then CFO. Any white paper with a market analysis would suggest the same.

J&J offered Actelion $30 billion. This was 13 times sales. I know someone who works there and they are just scratching their head.

icon url

stevo99

12/24/16 11:43 AM

#166576 RE: Jhawker #166565

Makes me think Leo should take Purisol to market......"If Actelion were to go out at around $30 billion, this equates to around 13 times sales and 30 times earnings before interest and taxes. These are high figures."

Let me see we get Purisol to $2-3 Billion in sales by 2020ish and boom $30 Billion sale of Purisol anyone.....